Pre-diagnostic blood selenium status and mortality among gastric cancer patients from Western European populations.
文献摘要
Background Gastric cancer remains one of the most lethal malignant tumors worldwide. Whether selenium status before diagnosis is associated with survival following gastric cancer diagnosis remains unclear. Methods Among 653 patients diagnosed with gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we examined associations of pre-diagnostic plasma selenium (Se), selenoprotein P (SELENOP) concentrations, and glutathione peroxidase 3 (GPX3) activity with gastric cancer-specific and overall mortality using multivariable Cox proportional hazards models. Results Blood samples were collected an average of 8.8 years before diagnosis. During follow-up, 483 patients died, including 359 from gastric cancer. The median observed time from diagnosis to death or censoring was 1.3 years. Multivariable-adjusted HRs (95% CIs) per one-SD increase in Se, SELENOP, and GPX3 were 0.95 (0.83-1.09), 0.94 (0.82-1.07), and 1.00 (0.88-1.14), respectively, for gastric cancer-specific mortality, and 0.97 (0.87-1.09), 0.94 (0.84-1.05), and 0.98 (0.87-1.09) for overall mortality. Conclusions Pre-diagnostic biomarkers of selenium status were not clearly associated with gastric cancer-specific or overall mortality in this cohort. Further studies in populations with different selenium exposure distributions are needed to assess the generalizability of these findings and to replicate exploratory subgroup results.